ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "e010029b-3ea3-4899-a282-345506c2d274"}, "_deposit": {"id": "8013", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "8013"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00008013", "sets": ["883"]}, "author_link": ["21995", "21996", "21997", "21998", "21999", "22000", "22001", "22002", "22003"], "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "796", "bibliographicPageStart": "794", "bibliographicVolumeNumber": "46", "bibliographic_titles": [{"bibliographic_title": "TRANSPLANTATION PROCEEDINGS"}]}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction. Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. Patients and Methods. This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. Results. The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. Conclusions. We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "TRANSPLANTATION PROCEEDINGS. 46(3):794-796 (2014)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "Mita, A", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.gFTNHVkh.html"}, {"subitem_link_text": "Ikegami, T", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.WpcCHFkh.html"}, {"subitem_link_text": "Ohno, Y", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.jUSVbaym.html"}, {"subitem_link_text": "Nakazawa, Y", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.uFyCuUkh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000335294900035"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "ELSEVIER SCIENCE INC"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "24767351"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/24767351", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1016/j.transproceed.2014.01.006"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.transproceed.2014.01.006", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright© 2014 Elsevier Inc."}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0041-1345", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0041-1345", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00868957", "subitem_source_identifier_type": "NCID"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Introduction. Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. Patients and Methods. This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. Results. The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. Conclusions. We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1."}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mita,  A", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21995", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikegami,  T", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21996", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuda,  Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21997", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyama,  Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohno,  Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Urata,  K", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakazawa,  Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi,  A", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyagawa,  S", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22003", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-25"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Optimal_initial_dose_orally_administered.pdf", "filesize": [{"value": "652.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 652800.0, "url": {"label": "Optimal_initial_dose_orally_administered.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/8013/files/Optimal_initial_dose_orally_administered.pdf"}, "version_id": "61c5a1ae-ad26-4305-af8a-75b846867d9c"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["883"], "permalink_uri": "http://hdl.handle.net/10091/17694", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2014-07-09"}, "publish_date": "2014-07-09", "publish_status": "0", "recid": "8013", "relation": {}, "relation_version_is_last": true, "title": ["Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation"], "weko_shared_id": -1}
  1. 055 医学部附属病院
  2. 0551 学術論文

Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation

http://hdl.handle.net/10091/17694
http://hdl.handle.net/10091/17694
029cca71-07b0-4f1a-9f77-670f70467247
名前 / ファイル ライセンス アクション
Optimal_initial_dose_orally_administered.pdf Optimal_initial_dose_orally_administered.pdf (652.8 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2014-07-09
タイトル
言語 en
タイトル Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ journal article
著者 Mita, A

× Mita, A

WEKO 21995

en Mita, A

Search repository
Ikegami, T

× Ikegami, T

WEKO 21996

en Ikegami, T

Search repository
Masuda, Y

× Masuda, Y

WEKO 21997

en Masuda, Y

Search repository
Katsuyama, Y

× Katsuyama, Y

WEKO 21998

en Katsuyama, Y

Search repository
Ohno, Y

× Ohno, Y

WEKO 21999

en Ohno, Y

Search repository
Urata, K

× Urata, K

WEKO 22000

en Urata, K

Search repository
Nakazawa, Y

× Nakazawa, Y

WEKO 22001

en Nakazawa, Y

Search repository
Kobayashi, A

× Kobayashi, A

WEKO 22002

en Kobayashi, A

Search repository
Miyagawa, S

× Miyagawa, S

WEKO 22003

en Miyagawa, S

Search repository
信州大学研究者総覧へのリンク
氏名 Mita, A
URL https://soar-rd.shinshu-u.ac.jp/profile/ja.gFTNHVkh.html
信州大学研究者総覧へのリンク
氏名 Ikegami, T
URL https://soar-rd.shinshu-u.ac.jp/profile/ja.WpcCHFkh.html
信州大学研究者総覧へのリンク
氏名 Ohno, Y
URL https://soar-rd.shinshu-u.ac.jp/profile/ja.jUSVbaym.html
信州大学研究者総覧へのリンク
氏名 Nakazawa, Y
URL https://soar-rd.shinshu-u.ac.jp/profile/ja.uFyCuUkh.html
出版者
出版者 ELSEVIER SCIENCE INC
引用
内容記述タイプ Other
内容記述 TRANSPLANTATION PROCEEDINGS. 46(3):794-796 (2014)
書誌情報 TRANSPLANTATION PROCEEDINGS

巻 46, 号 3, p. 794-796, 発行日 2014-04
抄録
内容記述タイプ Abstract
内容記述 Introduction. Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. Patients and Methods. This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. Results. The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. Conclusions. We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1.
資源タイプ(コンテンツの種類)
内容記述タイプ Other
内容記述 Article
ISSN
収録物識別子タイプ PISSN
収録物識別子 0041-1345
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA00868957
PubMed
識別子タイプ PMID
関連識別子 https://pubmed.ncbi.nlm.nih.gov/24767351
関連名称 24767351
DOI
識別子タイプ DOI
関連識別子 https://doi.org/10.1016/j.transproceed.2014.01.006
関連名称 10.1016/j.transproceed.2014.01.006
権利
権利情報 Copyright© 2014 Elsevier Inc.
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
WoS
表示名 Web of Science
URL http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000335294900035
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 07:13:42.464937
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3